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This workshop, 'In Vivo Percutaneous Pene t ra t ion /Absorp t ion '  was held in Washington,  DC, on May 1-3, 1989. The first 
workshop in this series, "In Vitro Percutaneous Penetration' ,  took place in November 1986 (the report of this earlier meeting was 
published in Pharmaceutical Research, 4 (1987) 265-267). The objectives of the workshop were to review the relevant literature and 
to address in detail: (1) In vivo percutaneous  pene t ra t ion /absorp t ion  methodology; (2) The characteristics of dosage forms 
designed for application to the skin; (3) Critical factors controlling in vivo drug transport into and across the skin: (4) The use of 
models in the assessment  and evaluation of in vivo percutaneous pene t ra t ion /absorp t ion ;  and (5) Bioavailabili ty/bioequivalencc 
considerations for topical drug products. Scientific knowledge and technology are rapidly evolving in the topical and transdermal 
drug products area. This report focuses on the methodologies available for the measurement  of percutaneous penetrat ion in vivo; 
each scientific approach is discussed briefly followed by advantages and disadvantages of the methodology. 
Introduction 
Drug products applied to the skin can be sub- 
divided into two categories: 
(1) Dermatological formulations (creams, oint- 
ments, gels, lotions) intended for the treatment of 
local (i.e., application site) skin disorders. 
(2) Transdermal delivery systems (ointments and 
patches) intended for the treatment or prevention 
of systemic disease. 
The skin is a barrier to the absorption of 
topically administered drugs (Schaefer et al., 1982; 
Barry, 1983; Bronaugh and Maibach, 1989). As a 
result, the rate of percutaneous transport is typi- 
cally slow, and the extent of drug delivery, al- 
though concentrated in the skin beneath the ap- 
plication site, is usually low. One advantage of 
these features is that the incidence of systemic 
toxicity in topical therapy is far less than that 
encountered with systemic routes of drug delivery 
(e.g., oral). Still, topical therapy may fall short of 
delivering a clinically sufficient local concentra- 
tion of drug. In such an instance, drug penetra- 
t i on /  absorption/bioavailabili ty can be increased 
through the use of chemical enhancers or through 
physical enhancing techniques such as ion- 
tophoresis and ultrasound. A general problem in 
ascertaining bioavailabi l i ty/bioequivalence of 
topical drug therapy is that quantification of the 
drug in the body (skin a n d / o r  systemic circula- 
tion) is difficult because the absolute amounts of 
drug present are (generally) too small. In vivo 
drug penetration studies following topical appli- 
cation may clarify the poorly resolved bioavail- 
abili ty/bioequivalence issues. 
The specific aims of in vivo skin penetration 
studies may be summarized as: 
(a) To verify and quantify the cutaneous bioavail- 
ability of a topically applied drug. 
(b) To verify and quantify the systemic bioavail- 
ability of a transdermally delivered drug. 
(c) To establish the bioequivalence of different 
topical formulations of the same drug. 
(d) To determine the incidence of and, if neces- 
sary, to quantitate local and systemic toxicological 
risk following the topical application of a specific 
drug. 
Each of the in vivo percutaneous absorpt ion/  
penetration approaches discussed at the work- 
shop is now considered in turn. Typically, follow- 
ing an introductory outline of the method, the 
consensus advantages and drawbacks are listed. 
Finally, our conclusions are summarized, and fu- 
ture research directions are highlighted. 
Animal Models 
It is important to emphasize at the outset that 
the most relevant in vivo data on percutaneous 
absorption in man will be obtained from studies 
in humans themselves (Guy et al., 1987b). How- 
ever, animal models are needed for the develop- 
ment of conceptual insights and to investigate 
mechanisms. If the study objective is prediction 
of percutaneous absorption in man, then rate and 
extent of skin absorption in the animal should be: 
(1) quantitatively the same as in man; or (2) 
consistently related to the absorption in man by a 
constant ratio. Moreover, the animals chosen for 
the studies must respond to treatments (e.g., ve- 
hicle effects, especially the use of enhancers) in 
the same way and to roughly the same degree as 
in man (Bond and Barry, 1988; Choi et al., 1990). 
On the basis of the currently available data, the 
only animals in which permeation data are consis- 
tently qualitatively and quantitatively similar to 
human permeation data, are the pig (Reifenrath 
et al., 1984) (particularly the weanling pig), the 
Rhesus monkey (Wester and Maibach, 1989) and 
the hairless rat (Rougier et al., 1987). However, it 
should be noted that the extra body fat on the pig 
may alter drug distribution relative to man and 
thereby confound the results. In the case of the 
Rhesus monkey, skin applications should be lim- 
ited to the non-hairy regions on the ventral sur- 
faces of the animal. Regional variation in skin 
properties (thickness, composition, etc.) in animal 
and man should be considered. Absorption stud- 
ies in the guinea pig are sometimes predictive of 
results in man but skin absorption rates in the 
rabbit, rat and mouse, appear to be substantially 
greater than that in man (Bartek et al., 1982; 
Reifenrath et al., 1984). Furthermore,  some labo- 
ratory animals do not consistently respond to 
treatments (e.g., with an absorption enhancer) in 
the same fashion as man; rather, they seem to be 
considerably more responsive to such treatments 
(Bond and Barry, 1988). 
Collection of Permeated Drug in Blood, Urine, 
and Tissues 
General. The drug pene t ra t ion /absorp t ion  
studies performed should differentiate: (1) der- 
matological, topical drug products from transder- 
real therapeutic drug products; (2) toxicologic 
studies from toxicokinetic studies; and (3) devel- 
opmental studies from clinical studies. All tech- 
niques must consider the benefits of using radio- 
labeled versus non-radiolabeled analytical (e.g., 
HPLC) methodology. 
Four approaches, which sample drug levels in: 
(a) the skin; (b) the venous blood draining the 
application site; (c) the systemic circulation; and 
(d) the excreta, can be identified. Principles of 
pharmacokinetics can be used when the drug 
concentrations are followed over time. For exam- 
ple, coupled with clearance parameters measured 
from intravenous administration, such data can 
be used to estimate the absolute extent of sys- 
temic bioavailability of a topically or transder- 
mally applied drug. Using this methodology, drug 
application to both normal and pathological skin 
can be considered. For topical dermatological 
products, toxicokinetic and safety studies should, 
when possible, be performed in the same species. 
Skin Sectioning 
Definition. Cutting, stripping or otherwise sep- 
arating skin into its constituent layers for inde- 
pendent assay of their drug content (Schaefer et 
al., 1978; Schaefer and Lamaud, 1987). 
Adt~antages. The technique can establish distri- 
bution and disposition of a given compound in 
the tissue as a function of time and tissue depth 
following application under various conditions 
(different vehicles, diseased skin, etc.). The pro- 
cedure is best performed in vivo but can, under 
well-defined circumstances, be conducted in vitro 
as well. 
Disadt,antages. Skin sectioning cannot nor- 
mally be performed in vivo in humans unless 
limited to punch biopsies. If the experiments are 
performed in vitro, their relevance is greatest for 
short application times. The technique is gener- 
ally limited to radiolabeled studies. The samples 
collected from the treated skin site in the experi- 
ments do not indicate the drug target nor the 
ultimate fate of the drug in the body. Assess- 
ments of metabolic processes and metabolites are 
especially difficult (Guzek et al., 1989). 
Sampling of Excreta 
Definition. Sampling of urine, feces, and ex- 
pired air for drug content following a topical 
administration (Guy et al., 1987b). 
AdL,antages. This is useful to assess total ab- 
sorption. It is relatively non-invasive, and can be 
routinely performed in human subjects. Mass bal- 
ance of the applied dose must be performed 
(Bucks et al., 1988). 
Disaduantages. A control study involving par- 
enteral injection of the drug is required. Avail- 
ability of a radiolabeled drug or a sensitive chem- 
ical assay is necessary. Metabolism of the drug by 
the skin a n d / o r  systemic metabolism may con- 
found precise bioavailability measurements. The 
technique has limitations for drugs which are 
naturally present in the body (e.g., certain 
steroids). The approach is difficult to apply to fat 
soluble drugs with long elimination half-lives. 
Blood Sampling 
Definition. Periodic sampling of blood as rou- 
tinely performed in all standard pharmacokinetic 
analyses. 
Aduantages. For drugs delivered transdermally 
to elicit systemic pharmacological effect, assay of 
drug levels in the b lood /p lasma  is essential. Drug 
concentrations of the order of those achieved by 
other administration routes are anticipated. A 
highly specific and sensitive assay may be neces- 
sary permitting high quality pharmacokinetic data 
to be obtained. Parent drug and metabolites can 
be identified and quantitated. With an intra- 
venous 'control', absolute bioavailability can be 
determined. 
Disadcantages. The method is generally unsuit- 
able for assessment of locally active dermatologic 
preparations because relationships between sys- 
temic and locally effective levels are unclear. The 
blood concentrations are typically too low for 
bioavailability assessment. Interference by en- 
dogenous substances can also prove problematic. 
Skin Flap Models 
Definition. In these techniques, tissue is surgi- 
cally prepared so that the blood vessels nourish- 
ing and draining the tissue can be directly ac- 
cessed. Xenografts (human skin transplanted onto 
an animal model) may be involved (Reifenrath et 
al., 1984; Wojchiechowski et al., 1987; Williams et 
al., 1990). 
Aduantages. The skin flap models are useful 
for studies addressing topical drug bioavailability, 
transdermal delivery and toxicological/toxicoki- 
netic evaluation. The technique allows assess- 
ment of mechanistic questions (e.g., dermal meta- 
bolism, cutaneous distribution, effect of blood 
flow on percutaneous absorption) not easily ad- 
dressed by other approaches. 
Disaduantages. The skin flap model is rela- 
tively expensive and, at this time, technically de- 
manding and labor-intensive. Animals, on which 
skin flaps with xenografts are raised, must be 
treated systemically with immunosuppressive 
drugs (e.g., cyclosporine); the effect of this treat- 
ment on skin barrier function is unclear. 
Residual Analysis - 'Difference', 'Disappearance' 
Methods 
Definition. Techniques in which the amount of 
drug absorbed into the skin are assessed as the 
difference between the amount applied and that 
recovered at a subsequent time. 
Two approaches have been described: (a) Af- 
ter drug application for a fixed time, the residual 
formulation is washed from the skin surface, and 
the amount removed is analyzed (Yano et al., 
1986). This is a single point determination 
(amount absorbed = (amount applied) - (amount 
remaining)). (b) The formulation is applied and 
drug content in the outer skin layers is then 
followed as a function of timc by spectroscopic 
(e.g., infrared) or radioisotopic monitoring tech- 
niques (Guy et al., 1987a; M a k e t  al., 1990). 
Approach (a): single point measurements of drug 
disappearance 
Adt,antages. The procedure requires very small 
amounts of active formulation. Skin toxicology 
concerns, while present, are minimal due to the 
limited exposure (drug amount and skin area). 
The method is inexpensive and relatively rapid. It 
is suitable for clinical studies. Radioisotope use is 
reasonable, due to the very low levels required; 
the radioisotopes need not have high specific 
activities; very little isotope is consumed. 
DisadL,antages. Only one assay per site per 
application is possible; full characterization of the 
drug uptake profile requires multiple site studies. 
Uniform recovery from different sites must be 
demonstrated. Drug removed inadvertently from 
the surface (on clothing, etc.) or by evaporation 
may be counted as absorbed. For poorly penetrat- 
ing compounds, the method quantitates the small 
difference between two large numbers. The appli- 
cation technique is critical; the amount applied 
and uniformity of spreading must be validated 
and reproducible. The method does not lend 
itself to theoretical analysis (separation of non- 
stationary state from steady or quasi-steady state 
periods of diffusion is virtually impossible). An- 
other potential problem is that the material used 
(soap solution, solvent, etc.) to remove the re- 
maining preparation from the skin surface may 
influence drug penetration. Furthermore,  the 
procedure does not actually measure the amount 
of drug at the target tissue in the skin. In other 
words, this type of measurement fails to reflect 
diffusive migration of drug into the critical zone, 
i.e., the region where the pharmacodynamic, 
pharmacological or biochemical event of rele- 
vance takes place. 
Approach (b): continuous or periodic monitoring of 
drug uptake 
The drug, radiolabeled (preferably) with 14C, 
or containing a non-ambiguous spectrophotomet- 
ric marker, is applied to the skin surface in the 
test formulation. Over time, the disappearance of 
radioactivity or of spectral signal is monitored 
using, for example, an appropriate Geiger-Muller 
tube or attenuated total reflectance, Fourier 
transform infrared spectroscopy (ATR-FTIR).  
Penetration kinetics are assessed from the decay 
of the respective signal. 
AdL, antages. Pharmacologically insignificant 
drug doses can be used. Full characterization of 
the drug uptake profile from a single experiment 
is possible. The method is relatively sensitive. 
The methods are non-invasive; they are also pre- 
cise and objective. 
DisadL, antages. (i) Radiometric methods: the 
use of radioisotopes on human subjects is neces- 
sary. The application of the method for bioequiv- 
alence measurements has not been demonstrated. 
Again, one is not measuring drug levels at the 
target site. (ii) Spectrophotometric methods: 
spectrophotometric interference is a major prob- 
lem. Optimal application of the technique re- 
quires that the drug has one or more unique 
spectral features that distinguish it from the spec- 
tral characteristics of the skin. However, provid- 
ing the drug with selected carbon-deuter ium sub- 
stitutions (for regular C-H bonds) could general- 
ize the approach. The equipment is specialized 
and costly. As with radioisotope monitoring, one 
is not measuring drug levels at the target site. 
In Vivo Measurement  of Drug Concentrations in 
Stratum Corneum: Prediction of Penetration 
This is a technique in which the permeability 
of drug is projected from the amount recovered 
in the stratum corneum by adhesive tape-strip- 
ping at a fixed time following drug application 
[20]. The method depends upon a correlation 
between short-time uptake by the stratum cor- 
neum and total percutaneous absorption. 
Adt,antages. The method requires pharmaco- 
logically insignificant drug doses; the experiment 
is straightforward and inexpensive; radiolabeled 
drugs are not essential if the compound can be 
efficiently extracted from the tape-strips for con- 
ventional analysis; comparisons between formula- 
tions are easily performed, and can be well-con- 
trolled. 
Disadt,,antages. Quantification of drugs in the 
stratum corneum tape-strips has generally been 
limited to radioisotope counting. Other ap- 
proaches have yet to be optimized and validated. 
The correlation between the amount of the drug 
in the stratum corneum and total drug absorption 
has only been established for some drugs and 
formulations. Since different body sites of skin 
have different drug penetration properties, the 
site of application has to be specified for predict- 
ing drug absorption like for any other method. 
The method does not sample the epidermis or 
the dermis (i.e., the normal 'targets' of topical 
drug products). The cleaning and preparation of 
the skin for stripping is a critical determinant of 
drug recovery. 
Mathematical Models in the Assessment of In 
Vivo Percutaneous Penetration/Absorption 
Mathematical (mechanistic) models of percu- 
taneous penetration have been utilized to simu- 
late drug delivery from the formulation, drug 
movement through skin into the cutaneous circu- 
lation, and the subsequent systemic distribution, 
metabolism and excretion (Berner, 1987; Berner 
and Cooper, 1987; Hadgraft, 1990; McDougal ct 
al., 1990; Osborne, 1990). Using appropriate pa- 
rameters, this approach may lead to experimenta- 
tion with novel systems. Mathematical models of 
percutaneous absorption have been developed to 
extrapolate in vitro measurements to in vivo data, 
to test mechanistic hypotheses, and to interpret 
data. 
Bioavailability / Bioequivalence Considerations 
For topical dermatological products, a measur- 
able pharmacodynamic response a n d / o r  quantifi- 
cation of the amount of drug absorbed /pene -  
trated at the target site can be regarded as a 
measure of drug availability (bioavailability) from 
the dosage form (Guy et al., 1986; Caron et al., 
1990). On the other hand, for transdermal drug 
products, measurement of systemic drug concen- 
trations a n d / o r  pharmacodynamic response pro- 
vide the necessary evidence of drug bioavailabil- 
ity. 
Cutaneous bioavailability can be assessed by 
performing, as a function of time: (1) pharma- 
cokinetic measurements of the drug concentra- 
tions in the skin or systemic circulation; or (2) 
pharmacodynamic measurements of the pharma- 
cological response to the drug in the skin or 
elsewhere. 
The combination of the two methods allows 
one to investigate problems of principal impor- 
tance and subsequently to choose one of the two 
approaches for more routine purposes. 
Pharmacodynamic Responses for Assessing 
Bioavailability and Bioequivalence of Topical 
Dermatological Products 
Pharmacodynamic responses in skin function 
can serve as proof, and as measures, of local 
absorption. To date, vascular responses have been 
used in this way. The pharmacodynamic assays 
are worth pursuing (in particular, the skin blanch- 
ing assay for glucocorticoids), but require devel- 
opment and generation of a rigid worldwide pro- 
tocol before they can be used for bioavailability/ 
bioequivalence determinations with confidence 
(Barry, 1983, 1989). 
Aduantages. There is a long history with these 
assays (in particular, the vasoconstriction or skin 
blanching assay) in dermatological research with 
glucocorticoids and there are good clinical effi- 
cacy correlations. The methods are internally 
consistent, and for clinical studies, they are inex- 
pensive and facile. The assays are qualitatively 
reliable and have proven useful for evaluating 
vehicle effects on drug absorption. 
Disaduantages. Only a limited number of com- 
pounds (e.g., topical corticosteroids) evoke a 
strong local pharmacological response and lend 
themselves to the pharmacodynamic method. 
Pharmacodynamic responses are difficult to vali- 
date. The methods require a rigid protocol. The 
pharmacodynamic measurements are subjective, 
and there is a need, therefore, to develop objec- 
tive methods to quantify these pharmacodynamic 
responses (Queille-Roussel et al., 1991). For most 
topical drug products, the dose-response curves 
are yet to be defined. The 'area under the curve' 
(AUC) (response versus time) type of measure- 
ments and calculations are a necessary part of the 
evaluation. 
Bioavailability/Bioequivalence of Transdermal 
Delivery Systems 
Pharmacokinetic and pharmacodynamic stud- 
ies are required as appropriate for innovator and 
generic drug products which are designed to elicit 
a systemic pharmacological effect. Special atten- 
tion should be paid to the occurrence and sever- 
ity of local (i.e., application site) skin reactions. 
Appropriate irritation and sensitization studies 
must be performed. Although these requirements 
are expensive and time-consuming, they are es- 
sential. Since transdermal drug products are ad- 
ministered for systemic effects, it is desirable to 
measure drug/metabol i te  concentrations in 
blood/plasma and/or  urine. 
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